Abstract: Trastuzumab is a humanized monoclonal antibody that targets Human epidermal growth factor receptor 2(Her2) proto-oncogenes, which can act on Her2 over-expression of tumor cells, inhibits tumor cells proliferation, differentiation, migration and other physiological activities, reduces the risk of tumor metastasis and extend the survival time of patients.

Key words: HER2, Trastuzumab, Tumor targeted therapy, Mechanisms, Research advances